Search Results

Your search for Sherene Loi, MD, PhD matches 2 pages

Showing 1 - 2

By Matthew Stenger / Thursday, June 4, 2015 2:58 PM

Higher Tumor-Infiltrating Lymphocyte Level Associated With Better Outcomes in HER2-Positive Early Breast Cancer Independent of Neoadjuvant Treatment

In an analysis of the NeoALTTO trial reported in JAMA Oncology, Salgado et al found that a higher level of tumor-infiltrating lymphocytes was associated with improved pathologic compete response rate and event-free survival independent of neoadjuvant treatment received in patients with...

issues in oncology

breast cancer

By The ASCO Post Staff / Wednesday, December 11, 2013 2:22 PM

High Levels of Immune Cells in Tumors May Identify Breast Cancer Patients Most Likely to Benefit From Trastuzumab

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab (Herceptin), according to results presented today at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-05)....

Apr

Today In Oncology

Search Results

Your search for Sherene Loi, MD, PhD matches 2 pages

Higher Tumor-Infiltrating Lymphocyte Level Associated With Better Outcomes in HER2-Positive Early Breast Cancer Independent of Neoadjuvant Treatment

High Levels of Immune Cells in Tumors May Identify Breast Cancer Patients Most Likely to Benefit From Trastuzumab

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being